Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
2.730
+0.100 (3.80%)
Dec 23, 2024, 2:24 PM EST - Market open
Pasithea Therapeutics Employees
Pasithea Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 7 or -46.67% compared to the previous year.
Employees
8
Change (1Y)
-7
Growth (1Y)
-46.67%
Revenue / Employee
n/a
Profits / Employee
-$1,971,885
Market Cap
3.46M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | -7 | -46.67% |
Dec 31, 2022 | 15 | 10 | 200.00% |
Dec 31, 2021 | 5 | 2 | 66.67% |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
China Pharma Holdings | 231 |
Sharps Technology | 57 |
Helius Medical Technologies | 22 |
Theriva Biologics | 22 |
Azitra | 10 |
Enveric Biosciences | 7 |
GlucoTrack | 6 |
Avenue Therapeutics | 3 |
KTTA News
- 4 weeks ago - Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Why Is Pasithea Therapeutics Stock Surging On Thursday? - Benzinga
- 3 months ago - Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 7 months ago - Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting - GlobeNewsWire